Home » Stocks » AQST

Aquestive Therapeutics, Inc. (AQST)

Stock Price: $3.42 USD -0.09 (-2.56%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $3.46 +0.04 (1.17%) May 7, 7:28 PM
Market Cap 123.85M
Revenue (ttm) 48.21M
Net Income (ttm) -53.93M
Shares Out 36.21M
EPS (ttm) -1.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $3.42
Previous Close $3.51
Change ($) -0.09
Change (%) -2.56%
Day's Open 3.49
Day's Range 3.38 - 3.67
Day's Volume 519,582
52-Week Range 3.38 - 9.46

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 6.82% and 21.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

3 days ago - Zacks Investment Research

WARREN, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patient...

3 days ago - GlobeNewsWire

Los Angeles, California--(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...

1 week ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "th...

1 week ago - Business Wire

New York, New York--(Newsfile Corp. - April 30, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) betwee...

1 week ago - Newsfile Corp

NEW YORK, April 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2...

1 week ago - PRNewsWire

Los Angeles, California--(Newsfile Corp. - April 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 29, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securi...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such i...

1 week ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $AQST #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)

1 week ago - Business Wire

Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 28, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive"...

1 week ago - Newsfile Corp

Los Angeles, California--(Newsfile Corp. - April 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutic...

1 week ago - Newsfile Corp

New York, New York--(Newsfile Corp. - April 25, 2021) - WHY: New York, N.Y., April 25, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeu...

1 week ago - Newsfile Corp

WARREN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address pati...

2 weeks ago - GlobeNewsWire

NEW YORK, April 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2...

2 weeks ago - PRNewsWire

New York, New York--(Newsfile Corp. - April 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) betwee...

3 weeks ago - Newsfile Corp

LOS ANGELES, April 9, 2021 /PRNewswire/ --  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aquesti...

4 weeks ago - PRNewsWire

NEW YORK, April 7, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class actio...

1 month ago - PRNewsWire

NEW YORK, April 1, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 20...

1 month ago - PRNewsWire

NEW YORK, March 31, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST).  Such investors are a...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 29, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) betwee...

1 month ago - Newsfile Corp

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and Septem...

1 month ago - Business Wire

LOS ANGELES, March 25, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aquest...

1 month ago - PRNewsWire

WARREN, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address pati...

1 month ago - GlobeNewsWire

LOS ANGELES, March 24, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired A...

1 month ago - PRNewsWire

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are ad...

1 month ago - PRNewsWire

BENSALEM, Pa., March 22, 2021 /PRNewswire/ -- Law Offices of Howard G.

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such i...

1 month ago - Newsfile Corp

New York, New York--(Newsfile Corp. - March 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) betwee...

1 month ago - Newsfile Corp

NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are ad...

1 month ago - PRNewsWire

NEW YORK, March 18, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class acti...

1 month ago - PRNewsWire

NEW YORK, March 17, 2021 /PRNewswire/ --   WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2,...

1 month ago - PRNewsWire

NEW YORK, March 17, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class ...

1 month ago - GlobeNewsWire

NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between Decemb...

1 month ago - GlobeNewsWire

LOS ANGELES, March 16, 2021 /PRNewswire/ --  Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming  April 30, 2021 deadline to file a lead plaintiff motion in the class action filed on b...

1 month ago - PRNewsWire

New York, New York--(Newsfile Corp. - March 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) betwee...

1 month ago - Newsfile Corp

LOS ANGELES--(BUSINESS WIRE)---- $AQST #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the class action fil...

1 month ago - Business Wire

NEW YORK, March 12, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc....

1 month ago - GlobeNewsWire

BENSALEM, Pa.--(BUSINESS WIRE)---- $AQST #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the case filed on behal...

1 month ago - Business Wire

New York, New York--(Newsfile Corp. - March 10, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive"...

1 month ago - Newsfile Corp

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.43% and 11.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

WARREN, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patie...

1 month ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and Septem...

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $AQST #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf o...

1 month ago - Business Wire

LOS ANGELES--(BUSINESS WIRE)---- $AQST #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors

1 month ago - Business Wire

Aquestive Therapeutics (NASDAQ:AQST) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.

1 month ago - Benzinga

NEW YORK, March 06, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aquestive...

2 months ago - GlobeNewsWire

LOS ANGELES, March 5, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aques...

2 months ago - PRNewsWire

NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) from December ...

2 months ago - GlobeNewsWire

About AQST

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with... [Read more...]

Industry
Biotechnology
IPO Date
Jul 25, 2018
Stock Exchange
NASDAQ
Ticker Symbol
AQST
Full Company Profile

Financial Performance

In 2020, AQST's revenue was $45.85 million, a decrease of -12.85% compared to the previous year's $52.61 million. Losses were -$55.78 million, -15.79% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for AQST stock is "Buy." The 12-month stock price forecast is 14.67, which is an increase of 328.95% from the latest price.

Price Target
$14.67
(328.95% upside)
Analyst Consensus: Buy